WEBINAR: Clinical Trials for Metastatic Triple Negative Breast Cancer

Register to Attend Online (Free)

You'll be able to join live while we record.
You are all registered!

You will get an email with all the information you'll need to connect.

We look forward to seeing you!
Oops! Something went wrong while submitting the form.

In this webinar, Dr. Jason Sager discusses standard treatments and innovative treatments available to patient in clinical trials. He reviews recent data and paper published that is advancing what we know about how to treat TNBC.

Get Your Own Cancer Questions Answered


0:00 - Introductions

1:03 - What is Triple Negative Breast Cancer?

5:05 - Defining Metastatic in Breast Cancer

6:51 - Standard Treatments for Metastatic Triple Negative Breast Cancer

8:50 - Why is my doctors recommending 24 weeks of chemotherapy and radiation prior to surgery?

16:33 - Involving a Radiation Oncologist and Medical Oncologist to your surgical team

18:53 - Reviewing a Treatment Recommendation

23:58 - NextGen Tumor Sequencing for TNBC and Matching to Clinical Trials

29:50 - Immunotherapy Trials in New England for TNBC

32:05 - Do you need to redo scans, biopsy, and tests if you get a second opinion at another cancer center?

34:15 - Using Existing Biopsy to get NextGen Sequencing performed

34:55 - Monitoring Triple Negative Breast Cancer for Recurrence. What does the latest data say?

41:39 - Testing strategies for proactive patients

References mentioned by Dr. Sager

FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer

FDG PET, PET/CT, and breast cancer imaging

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Long-term outcomes for neoadjuvant versus adjuvantchemotherapy in early breast cancer: meta-analysis ofindividual patient data from ten randomised trials

Jason Sager, MD is an oncologist and drug developer that helps patients understand their options and reach their best possible outcome.

Learn more about Dr Sager and Sagely Health.